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Objectives The purpose of this study was to investigate the effects of varespladib on cardiovascular biomarkers in acute
coronary syndrome patients.
Background Secretory phospholipase A2 (sPLA2) represents a family of proatherogenic enzymes that hydrolyze lipoprotein
phospholipids, increasing their affinity for intimal proteoglycans; contribute to cholesterol loading of macro-
phages by nonscavenger receptor mediated pathways; and activate inflammatory pathways. In prospective stud-
ies, high sPLA2-IIA levels predicted major adverse cardiovascular events in acute coronary syndrome (ACS) and
stable coronary heart disease patients.
Methods This randomized, double-blind, prospective controlled clinical trial (phase 2B) was designed to investigate the effects
of sPLA2 inhibition with varespladib 500 mg daily versus placebo as adjunctive therapy to atorvastatin 80 mg daily on
biomarkers (low-density lipoprotein cholesterol [LDL-C], high-sensitivity C-reactive protein [hsCRP], and sPLA2-IIA lev-
els), major adverse cardiovascular events (unstable angina, myocardial infarction, death), and safety. In all, 625 ACS
subjects were randomized within 96 h of the index event and treated for a minimum of 6 months.
Results After 8 weeks (primary efficacy end point), varespladib/atorvastatin reduced mean LDL-C levels from baseline by
49.6% compared with 43.4% with placebo/atorvastatin (p  0.002). Respective 8-week median reductions in
sPLA2-IIA levels were 82.4% and 15.6% (p  0.0001), and hsCRP levels were lowered by 75.0% and 71.0%
(p  0.097). At 24 weeks, respective reductions with varespladib and placebo were as follows: LDL-C 43.5% versus
37.6% (p  0.05), hsCRP 79.8% versus 77.0% (p  0.02), and sPLA2-IIA 78.5% versus 6.4% (p  0.0001). Major
adverse cardiovascular events were not different from placebo 6 months post-randomization (7.3% varespladib vs.
7.7% placebo). No treatment differences in elevated liver function studies on 1 occasion were observed.
Conclusions Varespladib therapy effectively reduced LDL-C and inflammatory biomarkers in ACS patients treated with con-
ventional therapy including atorvastatin 80 mg daily. There were no treatment differences in clinical cardiovas-
cular events. (FRANCIS [Fewer Recurrent Acute Coronary Events With Near-Term Cardiovascular Inflammation
Suppression]-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes;
NCT00743925). (J Am Coll Cardiol 2010;56:1079–88) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.015o
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cigh-dose statin therapy is evidence-based practice for
econdary prevention of cardiovascular events in acute cor-
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ccepted June 1, 2010.nary syndrome (ACS) patients (1), and guideline-directed
reatment to achieve “target levels” for low-density lipopro-
ein cholesterol (LDL-C) (2). However, the risk of cardio-
ascular events remains high among ACS patients treated
ith high-dose statin therapy.
Residual cardiovascular risk in statin-treated ACS pa-
ients has been associated with an LDL-C concentration
hat exceeds target levels, and a persistent systemic inflam-
atory state (3). C-reactive protein (CRP) is a biomarker of
ystemic inflammation that has been shown to predict
ardiovascular events in patients presenting with ACS and
reated with statins regardless of the achieved LDL-C level.
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Effects of Varespladib on Biomarkers in ACS September 28, 2010:1079–88However, a causal role of CRP in
atherothrombosis has not been
established (4-6). Other inflam-
matory proteins may be more
specific targets for reducing car-
diovascular risk, particularly in
ACS patients (7).
Secretory phospholipase A2
(sPLA2) represents a family of
isoenzymes that have direct and
indirect involvement in athero-
sclerosis (8). Human athero-
sclerotic lesions have been
shown to express 7 of 10 known
sPLA2 isoforms (9). In culprit
coronary lesions of humans pre-
senting with acute myocardial
infarction (MI), atherosclerotic
lesions contain abundant quan-
tities of sPLA2-IIA that are
detected both intracellularly in
macrophages of the intima and
in vascular smooth muscle cells
s well as in extracellular deposits (10). Expression of
roups IIA and V have been shown to contribute to
therosclerosis in transgenic murine models (11,12).
In population studies, high sPLA2-IIA levels have been
hown to predict coronary heart disease (CHD) events in
atients with stable CHD (13,14) and unstable angina (15),
ll-cause mortality in acute MI patients (16), and incident
ardiovascular events in apparently healthy persons (17,18).
Varespladib methyl (A-002, Anthera Pharmaceutical,
ayward, California), a novel selective sPLA2 inhibitor, has
een shown to lower levels of sPLA2-IIA by 90%,
DL-C by 12% to 18%, and high-sensitivity CRP (hsCRP)
y 20% to 40% in stable CHD patients (19,20). This
andomized, double-blind, prospective controlled clinical
rial (phase 2B) was designed to investigate the effects of
PLA2 inhibition with varespladib 500 mg daily versus
lacebo as adjunctive therapy to atorvastatin 80 mg daily on
iomarkers (LDL-C, hsCRP, and sPLA2-IIA levels), ma-
or adverse cardiac events (MACE [unstable angina, non-
atal MI, nonfatal stroke, urgent revascularization 60 days
ost-index event, and death]), and safety.
ethods
atient population. All patients provided written in-
ormed consent. Local and national ethics committees
pproved the study protocol in accordance with the Decla-
ation of Helsinki and Good Clinical Practice Guidelines.
tudy protocol. The FRANCIS (Fewer Recurrent Acute
oronary events with Near-term Cardiovascular Inflamma-
ory Suppression) study is a randomized, double-blind,
rospective controlled phase 2B clinical trial designed to
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CHD  coronary heart
disease
CRP  C-reactive protein
hsCRP  high-sensitivity
C-reactive protein
IL  interleukin
LDL  low-density
lipoprotein
LDL-C  low-density
lipoprotein cholesterol
Lp-PLA2  lipoprotein-
associated phospholipase A2
MACE  major adverse
cardiac events
MI  myocardial infarction
SPLA2  secretory
phospholipase A2nvestigate the effects of sPLA2 inhibition with varespladib p00 mg daily versus placebo as adjunctive therapy to
torvastatin 80 mg daily on biomarkers (LDL-C, hsCRP,
nd sPLA2-IIA levels), MACE (unstable angina, nonfatal
I, nonfatal stroke, urgent revascularization 60 days
ost-index event, and death), and safety after a minimum of
months of treatment. After screening, subjects were
ithdrawn from their prescribed statin and randomly as-
igned within 96 h of their index event by an interactive
oice response system to receive treatment with atorvastatin
0 mg daily and either placebo or varespladib 500 mg once
aily. Safety and efficacy data were collected at weeks 0
baseline), 2, 4, 8, 16, and 24, and monthly thereafter until
he last subject enrolled had completed 6 months of treat-
ent. Clinical event data were collected throughout the
tudy.
nd points. The primary end point was comparison of
ctive and placebo treatments with respect to percentage
hange from baseline to week 8 in LDL-C. Secondary
iomarker end points included comparison of active and
lacebo treatments with respect to change from baseline in
oncentrations of sPLA2-IIA and hsCRP. Assessment of
reatment on MACE after 6 months was also a secondary
nd point.
Treatment-emergent adverse events and serious adverse
vents along with electrocardiographic and hemodynamic
ata, clinical chemistry, and hematology evaluations were
sed to assess safety.
iochemical analysis. Plasma lipids and chemistry panels
nd hsCRP were measured in a central laboratory by
tandard procedures (Quest Diagnostics, Van Nuys, Cali-
ornia). The LDL-C concentrations were calculated. Secre-
ory PLA2-IIA concentration was analyzed by a quantitative
-site enzyme immunoassay (Cayman Chemical, Ann Ar-
or, Michigan).
tatistical analysis. Primary efficacy analysis was the com-
arison of percentage changes from baseline to week 8 on
DL-C between the varespladib group and placebo group.
ssuming a dropout rate of 10%, we estimated that a sample
ize of 133 subjects per group was needed to provide 90%
ower to detect a difference in LDL-C of 8% with a 2-sided
evel of significance of 0.05. The primary efficacy analysis
as performed using analysis of covariance, with baseline
alue as a covariate and factors for treatment group and
ountry. Because of nonnormality, changes in hsCRP,
nterleukin (IL)-6, and sPLA2 concentration were analyzed
n natural log-transformed data using the same analysis of
ovariance model as described in preceding text. The de-
endent variable was the difference of the logarithm of the
ollow-up value and the logarithm of the baseline value. The
roportion of subjects reporting the following were com-
ared with the chi-square test: LDL-C values of 1.8
mol/l [70 mg/dl]; CRP values of3 mg/l; LDL-C values
f 1.8 mmol/l [70 mg/dl], and CRP values of 1 mg/l.
All secondary end points were considered as descriptive
vidence of efficacy or safety and were analyzed without any
rocedures to account for multiple comparisons.
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September 28, 2010:1079–88 Effects of Varespladib on Biomarkers in ACSThe number of subjects with MACE was analyzed using
logistic regression model with factors for treatment and
ountry. Summary descriptive statistics were derived for
ndividual time points and for change and percent change
rom baseline. The SAS software version 9.1.3 (SAS Insti-
ute, Cary, North Carolina) was used to perform the data
nalysis.
Adverse events were coded using the MedDra dictionary,
ersion 12.1, and categorized by primary system organ class
nd preferred term, by intensity, and by causal relationship
o study agent. We assessed all adverse events that occurred
rom the start of administration of the first dose of study
rug until 28 days after administration of the last dose of
tudy drug.
esults
emographic characteristics. In total, 673 subjects were
creened, resulting in 625 subjects being randomly allocated
o the varespladib plus atorvastatin, 80 mg daily, and
tandard of care arm (n  313) or to placebo plus atorva-
tatin, 80 mg, and standard of care arm (n  312) (Table 1,
ig. 1). One subject in the placebo group never received
reatment. By chance, more subjects in the varespladib-
reatment groups had revascularization procedures before
he index event (p  0.0055), but not as treatment for the
ualifying index event. The treatment groups were balanced
n terms of subjects withdrawing, 84 (27%) in the varesp-
adib treatment group and 92 (30%) in the placebo group.
he most common reasons for withdrawal were screening
aboratory LDL-C and triglyceride values outside protocol
imits or nondiagnostic criteria for MACE, 32 (10%)
eporting in the varespladib group and 51 (16%) in the
lacebo group.
The treatment groups did not differ with respect to
emographic and baseline characteristics (Table 1). Overall,
he index event was unstable angina in 147 (23.6%),
on–ST-segment elevation MI in 218 (34.9%), and ST-
egment elevation MI in 259 (41.5%). The mean time from
ospitalization to randomization was 57.5 h.
The use of standard cardiovascular medications was
imilar between treatment groups. All subjects had ongoing
oncomitant medication at baseline, with 96% reporting the
se of aspirin, 84% beta-blocking agents, 84% agents acting
n the renin-angiotensin system, and only 10% statins. The
DL-C levels were similar between the treatment groups at
aseline. The mean baseline values for LDL-C were 3.40
mol/l [131 mg/dl] and 3.35 mmol/l [130 mg/dl] for the
arespladib group and placebo group, respectively.
fficacy. Treatment with varespladib reduced LDL-C lev-
ls by 49.6% compared with 43.4% for placebo from
aseline to week 8 (primary efficacy end point, p  0.0021)
Table 2). The interaction term for previous revasculariza-
ion by treatment interaction was not significant (p 0.16).
tatistical differences in favor of varespladib were preservedn other sensitivity analyses on the primary end point. iespective treatment-related reductions (least-squares
ean) at week 8 observed using a repeated-measures mixed-
odel analysis were 49.2% versus 43.3% (p  0.0014) and
9.2% versus 43.7% (p  0.004) in a per-protocol analysis.
avorable treatment-related effects of varespladib on
DL-C levels were maintained through 24 weeks of the
tudy: week 16, 43.8% compared with 36.6% (p  0.007);
nd week 24, 43.5% compared with 37.6% (p  0.03), as
emographics and Baseline Characteristics:ll SubjectsTable 1 Demographics and B seline Characteristics:All Subjects
Variable
Varespladib 500 mg 
Atorvastatin 80 mg
(n  313)
Placebo 
Atorvastatin 80 mg
(n  311)
Age, yrs 58.5 10.3 59.6 10.5
Male, % 73.5 75.9
Female, % 26.5 24.1
Caucasian 313 (100) 310 (99.7)
BMI, kg/m2 29.2 4.4 29.1 4.1
Prior CAD 214 (68.4) 222 (71.4)
Revascularization
Before index event 97 (31.0) 66 (21.2)
For treatment of index event 16 (5.1) 18 (5.8)
Cerebrovascular disease 18 (5.8) 6 (1.9)
Peripheral vascular disease 19 (6.1%) 23 (7.4)
Risk factors
Diabetes mellitus 84 (26.8) 87 (28.0)
Hypertension 271 (86.6) 274 (88.1)
Hyperlipidemia 120 (38.3) 109 (35.0)
Current cigarette smoking 73 (23.3) 68 (21.9)
Qualifying event
STEMI 132 (42.2) 127 (40.8)
Mean cTnI, ng/ml 15.5 21.4 50.5 310.2
Median CRP, mg/l 12.0 (0–222) 9.9 (0–377)
NSTEMI 114 (36.4) 104 (33.4)
Mean cTnI, ng/ml 4.1 8.2 3.7 10.5
Median CRP, mg/l 5.6 (1–204) 6.0 (0–300)
Unstable angina 67 (21.4) 80 (25.7)
Mean cTnI, ng/ml 0.7 22 0.4 1.3
Median CRP, mg/l 3.8 (0–30) 5.0 (0–83)
Mean time from index event
in-hospital to
randomization, h
56.6 24.5 58.4 24.5
Aspirin 290 (92.7) 283 (91.0)
Beta-blockers 263 (84.0) 263 (84.6)
Drugs acting on RA system 269 (85.9) 254 (81.7)
Lipid-modifying agents 36 (11.5) 24 (7.7)
Thrombolytic therapy 34 (10.9) 34 (10.9)
Antiplatelet therapy 131 (41.9) 124 (39.9)
Anticoagulant therapy 36 (11.5) 50 (16.1)
LDL-C, mmol/l 3.39 1.02 3.35 1.06
hsCRP, mg/l 8.2 (3.5–33.6) 8.9 (3.3–32.5)
sPLA2-IIA, pmol/l 22.4 (14.1–34.5) 24.8 (14.6–36.9)
IL-6, pg/ml 5.22 (2.79–12.10) 5.16 (2.69–10.94)
ata are expressed as mean  SD, n (%), or median (interquartile range).
ApoB  apolipoprotein B; BMI  body mass index; CAD  coronary artery disease; cTn1 
ardiac troponin 1; hsCRP  high-sensitivity C-reactive protein; IL  interleukin; LDL-C  low-
ensity lipoprotein cholesterol; NSTEMI  non–ST-segment elevation myocardial infarction; PLA2-
IA group IIA secretory phospholipase A2; RA renin-angiotensin; STEMI ST-segment elevation
yocardial infarction.llustrated in Figure 2.
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Effects of Varespladib on Biomarkers in ACS September 28, 2010:1079–88In addition to the mean reductions in LDL-C, the
roportion of subjects treated with varespladib with LDL-C
1.8 mmol/l [70 mg/dl] at week 8 was 70.3% compared
ith 59.9% of those treated with placebo (p 0.011) (Fig. 3).
t 16 weeks, the respective proportions in each treatment
roup were 64.3% and 48.3% (p  0.0005), and at 24
eeks, 61.5% and 50.0% (p  0.02).
Varespladib treatment-related median reductions in
sCRP were seen at all time points and were statistically
ignificantly different from placebo at week 16, 81.6% and
1.8% (p  0.002), absolute difference 1 mg/l (p  0.002),
nd at week 24, 79.8% and 77.0% (p  0.02), respectively.
greater proportion of varespladib-treated subjects re-
orted hsCRP values of 3 mg/l at all time points com-
ared with placebo, and these changes were statistically
ignificant at week 16, 75.1% compared with 64.0% (p 
.008), and at week 24, 78.2% compared with 68.8% (p 
.04). In addition, more subjects treated with varespladib
26.9%) had combined LDL-C levels 1.8 mmol/l [70
g/dl] and hsCRP 1 mg/l at 24 weeks than subjects
reated with placebo (15.9%, p  0.012) (Fig. 4).
Varespladib treatment reduced sPLA2-IIA levels at all
ime points through 16 weeks and at the end of the study.
o samples were taken between 16 weeks and the end of the
tudy. Respective median treatment-related decreases in
Figure 1 CONSORT Diagram
AE  adverse effect; CONSORT  CONsolidated Standards of Reporting Trials;
MACE  major adverse cardiac events.PLA2-IIA levels were 82.4% in varespladib-treated sub- aects and 15.6% in placebo-treated subjects (p  0.0001) at
weeks; 62.0% versus 12.1% (p  0.0001) at 16 weeks;
nd 78.5% versus 6.4% (p  0.0001) at the final study
isit (Fig. 3).
Total MACE was not different between treatments at the
nd of the study (7.3% varespladib vs. 7.7% placebo, p 
.93) (Table 3). There were no significant differences in
ardiovascular risk for any component of the composite of
ll-cause death, nonfatal MI, documented unstable angina
equiring urgent hospitalization, revascularization occurring
60 days after the index event, or fatal or nonfatal stroke.
he difference in mortality between treatments was not
tatistically significant: p  0.36 (odds ratio: 1.61, 95%
onfidence interval: 0.58 to 4.51; Fisher’s exact test p 
lasma Levels of Lipids and Inflammatoryrkers at Baseline and End of TreatmentTable 2 Plasma Levels of Lipids nd InflammatoryMarkers at Baseline and End of Treatment
Variable and Study Phase Varespladib 500 mg Placebo
sPLA2-IIA concentration,
pmol/l
n  189 n  186
Baseline 23.0 (0.41 to 407.4) 24.8 (1.3 to 522.8)
End point 4.83 (0.41 to 213.7) 21.4 (3.0 to 208.3)
Percent change 78.5 (99.7 to 1,898.7)* 6.4 (97.3 to 986.3)
Total cholesterol, mmol/l n  196 n  194
Baseline 5.43 1.21 5.36 1.13
Week 24 3.54 0.96 3.79 0.96
Percent change 32.9 19.1† 27.9 18.4
LDL-C, mmol/l n  179 n  184
Baseline 3.23 0.93 3.20 0.88
Week 24 1.72 0.72 1.91 0.68
Percent change 43.5 26.8‡ 37.6 25.6
Non–HDL-C, mmol/l n  196 n  194
Baseline 4.29 1.17 4.20 1.13
Week 24 2.42 0.89 2.63 0.91
Percent change 41.2 23.0‡ 35.6 21.5
VLDL-C, mmol/l n  183 n  189
Baseline 0.95 0.37 0.92 0.33
Week 24 0.68 0.30 0.65 0.29
Percent change 19.3 62.6 25.3 31.5
HDL-C, mmol/l n  196 n  194
Baseline 1.08 0.26 1.13 0.31
Week 24 1.10 0.26 1.14 0.28
Percent change 5.1 42.9 3.6 23.1
Triglycerides n  196 n  194
Baseline 2.28 1.13 2.09 0.88
Week 24 1.57 0.81 1.50 1.07
Percent change 21.3 59.0 23.6 45.7
hsCRP, mg/l n  188 n  189
Baseline 7.9 (0.2 to 202) 8.3 (0.3 to 258)
Week 24 1.3 (0.2 to 17.8) 1.6 (0.2 to 59.5)
Percent change 79.8 (99.8 to 871.4)‡ 77.0 (99.8 to 786.0)
Interleukin-6 n  267 n  246
Baseline 5.2 (0.5 to 126.6) 5.1 (0.5 to 272.1)
End point 3.1 (0.5 to 47.9) 3.0 (0.5 to 45.8)
Percent change 37.4 (98.4 to 920.3) 32.0 (97.7 to 1,503.3)
Data are expressed as mean  SD or median (range). To convert cholesterol values in mmol/l to
g/dl, multiply by 38.7; and to convert triglyceride values frommmol/l to mg/dl, multiply by 88.6.
p  0.001 versus placebo. †p  0.01 versus placebo. ‡p  0.05 versus placebo.
HDL-C  high-density lipoprotein cholesterol; VLDL  very low-density lipoprotein-C; other
bbreviations as in table 1.
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September 28, 2010:1079–88 Effects of Varespladib on Biomarkers in ACS.45). Furthermore, 2 of the deaths in the varespladib group
ccurred within 24 h of presentation of the index event after
he subject had received only a single dose of study drug. A
urther 4 subjects died in the placebo group within the
-month period after study completion compared with 1 in
he varespladib group.
afety. The median duration of exposure to both study
edication and atorvastatin was 224 days for varespladib
nd 223 days for placebo.
Adverse events were reported in 70% of varespladib-
reated subjects compared with 76% of placebo-treated
ubjects (p  0.12) (Table 4). Fewer subjects treated with
Figure 2 Effects of Varespladib on Cardiovascular Biomarkers
Data are expressed as least square mean  SE of low-density lipoprotein cho-
lesterol (LDL-C) and median (interquartile range) of high-sensitivity C-reactive
protein (hsCRP) and sPLA2-IIA concentration in placebo-treated patients (solid
circles) and varespladib-treated patients (open circles). Compared with pla-
cebo, varespladib reduced LDL-C, hsCRP, and sPLA2-IIA levels at each time
point except at week 8 for hsCRP. FSV  final study visit.arespladib reported treatment emergent adverse events telated to the renal tract compared with placebo: 10 (3.2%)
nd 19 (6.1%), respectively. Nine percent of subjects in each
roup reported events related to the study medication.
The only biochemical changes of note were transient
ncreases in alanine aminotransferase and aspartate amino-
ransferase. A total of 58 subjects reported liver function
ests 3 times the upper limit of normal at some time point
uring the course of the study: 31 (9.9%) subjects treated
ith varespladib and 27 (8.7%) treated with placebo (ator-
astatin 80 mg). All 58 subjects were asymptomatic, and the
umber withdrawn due to elevated serum transaminases was
imilar between the varespladib group (n  6) and placebo
roup (n  4). The proportions of subjects with amino-
ransferase or aspartate aminotransferase increases 3 times
he upper limit of normal on 1 occasion was not different
etween treatments: varespladib 3 (1.0%) and placebo 2
0.7%).
No varespladib treatment-related effects were observed on
lood pressure or the QT interval.
iscussion
his study of ACS patients treated with 80-mg atorvastatin
lus standard of care extends the understanding of the
reatment-related effects of varespladib on lipid and inflam-
atory biomarkers beyond that reported in stable CHD
atients (19,20). Varespladib was more effective than pla-
ebo in lowering biomarkers that identify patients at high
isk for recurrent cardiovascular events. The treatment
ifferences in LDL-C and hsCRP persisted over the dura-
ion of the 6-month trial. The study was not powered to
etect a difference in clinical events, and the number of
vents was small in both groups and not significantly
ifferent at the end of the study.
Varespladib methyl (1-H-indole-3-glyoxamide; A-002,
nthera Pharmaceuticals, Hayward, California; or previ-
usly LY333013, Eli Lilly & Co., Indianapolis, Indiana; or
3013, Shionogi & Company, Osaka, Japan) is the oral
rodrug of varespladib sodium (sodium 2-[1-benzyl-2-
thyl-3-oxamoylindol-4-yl]) oxyacetate; A-001, Anthera
harmaceuticals, or previously LY315920, Eli Lilly & Co.;
r S5920, Shionogi & Company), which is a small molecule
nhibitor of sPLA2 with specificity toward group IIA sPLA2
IC50: 9 to 14 nM), group V sPLA2 (IC50: 77 nM), and
roup X sPLA2 (IC50: 15 nM) (21). In 1 study, varespladib
as been shown to reduce the extent of aortic atherosclerosis
n ApoE/ mice fed a high fat diet for 2 weeks, and treated
ith varespladib methyl or placebo for 16 weeks (21). In a
tudy of accelerated atherosclerosis induced by a combina-
ion of high fat diet and continuous infusion of angiotensin
I, 4 weeks of treatment with varespladib methyl reduced
he extent of aortic plaque coverage and aneurysm formation
21). In ApoE/ mice fed a Western diet for 3 months,
ombined low doses of varespladib methyl (1.5 mg/kg daily)
nd pravastatin caused a greater decrease in atherosclerosis
han either drug when used alone, suggesting a synergistic
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Effects of Varespladib on Biomarkers in ACS September 28, 2010:1079–88ffect (22). Pravastatin combined with low-dose varespladib
ethyl reduced plaque area by 50%. These experimental
tudies provided a rationale for investigation into the role of
arespladib methyl in the treatment of atherosclerosis, and
he potential synergistic effect of varespladib methyl and
tatin therapy.
Previously, we reported that varespladib 500 mg daily
educed LDL-C from 12% to 18% in stable CHD patients,
hereas hsCRP was nonsignificantly reduced by 20% to 40%
19,20). In the prior studies of stable CHD patients, 8 weeks
f treatment with varespladib reduced sPLA2-IIA concentra-
ions by 90% and reduced LDL-C from 12% to 18%.
Several members of the sPLA2 family of enzymes catalyze
ydrolysis of surface phospholipids on lipoproteins, and
esult in structural alteration in these particles (8). The
nsuing conformational change in apolipoprotein B (23)
educes clearance of circulating very low-density lipoprotein
emnants and low-density lipoprotein (LDL) particle by the
polipoprotein B/E (LDL) receptor, resulting in increased
esidence time in the circulation that increases their suscep-
Figure 3 LDL-C Goal Attainment With Varespladib and Placebo
Percentage of patients who achieved goal low-density lipoprotein cholesterol (LDL-
in varespladib-treated patients (open bars) and placebo-treated patients (solid baribility to oxidative modification (24). In the vessel wall, the conformational changes in apolipoprotein B increase their
inding to intimal proteoglycans (23,25), promote retention
f these atherogenic lipoproteins in the vessel wall (26–28),
nd increase cholesterol accumulation in macrophages
29,30). It has been shown that inhibition of secretory
hospholipase A2 with varespladib increases LDL particle
ize and lowers LDL-C levels (19,20). The LDL-C lower-
ng effect is augmented with statin therapy (19), presumably
ecause of enhanced LDL receptor-mediated clearance of
he larger LDL particles.
Proinflammatory effects of sPLA2 derive from multiple
athways that include production of lysophosphatidylcho-
ine and nonesterified fatty acids (31), and direct effects on
ctivation of the mitogen-activated protein kinase pathway,
xtracellular signal-regulated protein kinase-1/2 activation,
nd increased release of arachidonic acid (32-36). Arachi-
onic acid is an important inflammatory lipid mediator that
ncreases expression of adhesion molecules on endothelial
ells, including intercelluar adhesion molecule-1 and vascu-
ar cell adhesion molecule-1, that subsequently causes in-
ls 1.81 mmol/l (70 mg/dl)
ach time point in the study.C) leve
s) at ereased adhesion of monocytes to endothelial cells (37).
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September 28, 2010:1079–88 Effects of Varespladib on Biomarkers in ACSAlthough the precise mechanism for the benefit of sPLA2
nhibition with varespladib treatment cannot be established
olely on the basis of the findings from this trial, similar
n-trial levels of LDL-C and hsCRP have been accompa-
ied by lower rates of MACE (3,37). In the PROVE
T–TIMI 22 (Pravastatin or Atorvastatin Evaluation and
nfection Therapy–Thrombolysis In Myocardial Infarction
2) trial, ACS patients were randomly assigned to atorva-
tatin 80 mg/day or pravastatin 40 mg/day (3). Among
reated patients with LDL-C levels of 1.8 mmol/l (70
g/dl) or higher and hsCRP levels of 2 mg/l or higher, the
isk of recurrent MI of CHD death was 4.6 per 100
erson-years, and 2.4 per 100 person-years for patients with
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Figure 4 Percentage of Treated Patients Who Achieved LDL-C
Percentage of patients who achieved low-density lipoprotein cholesterol (LDL-C) lev
levels 1 mg/l in varespladib-treated patients (blue bars) and placebo-treated pa
reakdown of Major Adverse Cardiac Eventst Week 16 and at En of StudyTable 3 Breakdown Major Advers Cardiac Eventsat Week 16 and at End of Study
Varespladib Placebo
Week 16
Overall, ITT analysis n  313 n  311
Total MACE 14 19
ITT event rate 4.2% 6.1%
UA requiring hospitalization 5 (1.6%) 9 (2.9%)
Myocardial infarction 2 (0.6%) 4 (1.3%)
Stroke 1 (0.3%) 1 (0.3%)
Death 6 (1.9%) 5 (1.6%)
Revascularization 60 days 0 (0%) 0 (0%)
End of study
Overall, ITT analysis n  313 n  311
Total MACE 23 24
ITT event rate 7.3% 7.7%
UA requiring hospitalization 8 (2.6%) 10 (3.2%)
Myocardial infarction 3 (1.0%) 6 (1.9%)
Stroke 1 (0.3%) 1 (0.3%)
Death 10 (3.2%) 6 (1.9%)
Revascularization 60 days 1 (0.3%) 1 (0.3%)wTT  intention to treat; MACE  major adverse cardiac events; UA  unstable angina.DL-C levels 1.8 mmol/l (70 mg/dl) and hsCRP levels
2 mg/l. In phase Z of the A-to-Z (Aggrastat-to-Zocor)
rial, more intensive statin therapy was not accompanied by
reduction in the incidence of the primary end point
cardiovascular death, MI, readmission for ACS, or stroke)
38). However, patients in the intensive therapy arm who
chieved both aggressive lowering of LDL-C (1.8 mmol/l
70 mg/dl]) and hsCRP reductions (2 mg/l) had lower
ardiovascular event rates.
Although CRP has been the most extensively studied
nflammatory biomarker associated with residual risk in
tatin-treated patients, sPLA2 is more proximate inflamma-
ory protein in the inflammatory cascade and a more specific
arget of therapy (7). Median secretory PLA2 and hsCRP
evels were elevated at baseline in both treatment groups,
ut the levels of these inflammatory proteins were even
igher among those subjects who had a secondary event
uring the course of the study: sPLA2 23.9 pmol/l versus
6.9 pmol/l, and hsCRP 8.6 mg/l versus 16.5 mg/l,
espectively.
Of the various sPLA2 isoenzymes, sPLA2-IIA is an acute
hase reactant expressed in arterial smooth muscle cells and
epatocytes that activates transcription factors that induce
ynthesis of proinflammatory cytokines such as tumor ne-
rosis factor-, IL-1, and IL-6 (8). These proinflamma-
ory cytokines induce hepatic and myocardial CRP. We
bserved an increase in sPLA2-IIA levels in ACS patients
hat preceded the rise in hsCRP levels. These temporal
ifferences in inflammatory markers are inconsistent with
he earlier activation of sPLA2 from leukocytes after acute
issue injury than is observed from hepatic synthesis of CRP
vident 48 to 72 h after an acute event (39). In this trial,
arespladib reduced acute phase mediated increases in
PLA2-IIA concentrations. As on-trial sPLA2-IIA levels
=0.6128
p=0.0130
p=0.0117
8 16 24
eek
s and hsCRP Levels
1.81 mmol/l (70 mg/dl) and high-sensitivity C-reactive protein (hsCRP)
(black bars) at each time point in the study.p
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ignificance of elevated sPLA2-IIA levels shown in ACS
atients (15,16).
Another phospholipase A2 inhibitor under clinical investi-
ation is lipoprotein-associated phospholipase A2 (Lp-PLA2)
7). The Lp-PLA2 inhibitor represents a calcium-independent
hospholipase that is predominantly synthesized by macro-
hages. In plasma, Lp-PLA2 is bound to LDL and high-
ensity lipoprotein, with a greater affinity for the polar surface
f LDL particles, particularly electronegative small LDL
articles that have been minimally oxidatively modified. The
equirement for a minimally oxidatively modified LDL particle
s one feature that distinguishes Lp-PLA2 from sPLA2 that
cts on native LDL. In a multicenter trial of stable CHD or
HD risk equivalent patients, treatment with darapladib 160
g daily reduced IL-6 levels by 12.3% (95% confidence
nterval: 22% to 1%, p  0.028) compared with placebo,
hereas there were no significant group differences in hsCRP
40). In this study, at week 2, varespladib also reduced median
L-6 levels by 16.6% compared with 5.2% for placebo (p 
.19). Treatment with darapladib has been shown to reduce
ipid necrotic core volume as assessed by intravascular ultra-
onography (41). The data from the IBIS-2 (Integrated Bi-
markers and Imaging Study-2) suggest that Lp-PLA2 inhi-
ition may reduce the vulnerability of rupture-prone plaques.
The FRANCIS study was primarily conducted as a
iomarker trial in ACS patients, and the findings in trial are
edDRA Summary of Treatment Emergent Adverse Events Occurrinr atment Group by Prim ry Syste Organ Class and Preferred TerTable 4 MedDRA Summar of Tr atment Emergent Adverse EvTreatment Group by Primary System Organ Class and P
MedDRA Primary System Organ Class and
Preferred Term
Varespladib 500 mg
(n 
No. of Reports No. o
Any 760
Cardiac disorders
Angina pectoris 13
Cardiac failure chronic 16
General disorders and administration site conditions
Asthenia 5
Infections and infestations
Respiratory tract infection 11
Respiratory tract infection viral 11
Investigations
Alanine aminotransferase increased 33
Aspartate aminotransferase increased 19
Blood alkaline phosphatase increased 9
Blood creatine phosphokinase increased 10
Blood glucose increased 12
C-reactive protein increased 55
Gamma-glutamyltransferase increased 36
Metabolism and nutrition disorders
Hyperglycemia 12
Nervous system disorders
Headache 15
Vascular disorders
Hypertension 12onsistent with the results reported in stable CHD patients P19,20). In the PLASMA I (Phospholipase Levels and
erological Markers of Atherosclerosis) and PLASMA II
rials, we also reported that varespladib was more effec-
ive than placebo treatment for lowering levels of LDL-C
nd sPLA2-IIA levels. In contrast to the earlier trials in
table CHD patients, we report significant treatment dif-
erences in hsCRP that occurred on a background of
igh-dose atorvastatin treatment. The reduction in hsCRP
n FRANCIS may result from the larger study population or
igher baseline hsCRP levels (median 8.6 mg/l in the
RANCIS study versus 1.10 to 1.89 mg/l in the PLASMA
and II trials). A secondary outcome of FRANCIS was a
ilot study of MACE. Although there were more deaths in
arespladib-treated subjects at week 24 (10 vs. 6), 2 subjects
ssigned to varespladib died within 24 h after ST-segment
levation MI. Six months after the trial, 1 additional patient
ied in the varespladib group and 4 subjects died in the
lacebo group. Based on a reduction in MIs and unstable
ngina among varespladib-treated patients, we have de-
igned a larger event-driven trial.
tudy limitations. Limitations of the current trial include
mall numbers of ACS patients that limit the ability to
etect differences in cardiovascular events. Nonetheless, the
rend toward reduction in MIs and unstable angina was seen
eyond maximal use of evidence-based therapies, inclusive
f high-dose atorvastatin. Second, serum sPLA2 activity
as not measured, as we previously reported in the
>3% in Eitherll Subjects PopulationOccurring in >3% in Either
rred Term: All Subjects Population
rvastatin 80 mg Placebo  Atorvastatin 80 mg
(n  311)
ects Reporting, n (%) No. of Reports No. of Subjects Reporting, n (%)
220 (70.3) 749 236 (75.9)
10 (3.2) 20 15 (4.8)
16 (5.1) 7 7 (2.3)
5 (1.6) 12 11 (3.5)
10 (3.2) 9 8 (2.6)
11 (3.5) 9 8 (2.6)
31 (9.9) 17 16 (5.1)
18 (5.8) 7 7 (2.3)
8 (2.6) 10 10 (3.2)
9 (2.9) 11 11 (3.5)
11 (3.5) 14 11 (3.5)
45 (14.4) 62 58 (18.6)
34 (10.9) 35 35 (11.3)
9 (2.9) 12 11 (3.5)
13 (4.2) 16 14 (4.5)
11 (3.5) 9 8 (2.6)g inm: Aents
refe
 Ato
313)
f SubjLASMA I trial, because low sPLA2-IIA concentration in
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September 28, 2010:1079–88 Effects of Varespladib on Biomarkers in ACShe samples from varespladib-treated subjects was below the
imit required for the activity assay (19); and, when sPLA2
nhibitors bind to the active site of sPLA2, the enzyme-
nhibitor complex binds tighter to membranes than does the
nzyme without inhibitor (42). Thus, it may be necessary in
he presence of inhibitor to measure total sPLA2 activity on
hole blood samples.
onclusions
he FRANCIS study demonstrates that treatment with
arespladib reduces concentration of LDL-C, hsCRP, and
PLA2 in ACS patients treated with evidence-based thera-
ies inclusive of high-dose atorvastatin. Elevated levels of
hese biomarkers have been shown to identify CHD pa-
ients who remain at high risk for recurrent cardiovascular
vents; however, in this trial, there were no treatment
ifferences in clinical cardiovascular events. A large, pro-
pective, double-blind, placebo-controlled trial in ACS
atients will be required to explore the future role of
arespladib treatment in cardiovascular event reduction.
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